[1]崔丽群,杨宝军.甲亢患者尿β2-微球蛋白、白蛋白、免疫球蛋白G联检及临床分析[J].国际放射医学核医学杂志,2009,33(6):356-358.[doi:10.3760/cma.j.issn.1673-4114.2009.06.012]
　GUI Li-qun,YANG Bao-jun.Joint detection and clinical analyse of urine β2-microglobulin,albumin and immunoglobulin G in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):356-358.[doi:10.3760/cma.j.issn.1673-4114.2009.06.012]
点击复制

甲亢患者尿β2-微球蛋白、白蛋白、免疫球蛋白G联检及临床分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
33
期数:
2009年第6期
页码:
356-358
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Joint detection and clinical analyse of urine β2-microglobulin,albumin and immunoglobulin G in patients with hyperthyroidism
作者:
崔丽群;  杨宝军
山西省晋中第一人民医院核医学科, 山西 030600
Author(s):
GUI Li-qun;  YANG Bao-jun
Department of Nuclear Medicine, First Hospital of Jinzhong, Shanxi Jinzhong 030600, China
关键词:
甲状腺功能亢进症; 放射免疫测定; β2微球蛋白; 白蛋白类; 免疫球蛋白G; 甲状腺激素类; 肾功能不全
Keywords:
Hyperthy-roidism; Radioimmunoassay; Beta 2-microglobulin; Albumins; Immunoglobulin G; Thyroid hormones; Renal insufficiency
DOI:
10.3760/cma.j.issn.1673-4114.2009.06.012
摘要:
目的 评价尿β2-微球蛋白(β2-MG)、白蛋白(Alb)、免疫球蛋白G(IgG)联检在甲亢患者中的临床意义。方法 放免法检测120例甲亢患者和45名健康体检者尿β2-MG、Alb、IgG和血清游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)水平,对各参数进行对比分析。结果 尿β2-MG、Alb、IgG水平在甲亢A(原发组)组与B组(未治愈组)中明显高于对照组及甲亢C组治愈组(t=6.682,P<0.01);甲亢B组又高于甲亢A组(t=2.385,P<0.05);甲亢C组与对照组无显着性差异(t=0.568,P>0.05)。甲亢组尿β2-MG、Alb、IgG分别与血清FT3、FT4水平具有较好的相关性,相关系数分别为0.98、0.88、0.93、0.87、0.94、0.85。结论 联合检测尿β2-MG、Alb、IgG对于早期发现甲亢患者肾功能损害、确定肾脏受损部位及肾小球损伤的程度等具有一定临床价值。
Abstract:
Objective To evaluate the clinical significance of joint detection of urine β2-microglobulin(β2-MG),albumin(Alb) and immunoglobulin G(IgG) in patients with hyperthyroidism. Methods Urine β2-MG, Alb, IgG and serum thyroid hormone free trilute(FT3), free thyroxin(FT4) of 45 healthy volunteers(as control group) and 120 patients with hyperthyroidism were measured by radioimmunoassay(RIA). Results The urine β2-MG, Alb and IgG in the hyperthyroidism group(including the primary group(group A) and uncured group(group B) ) were distinctly higher than those in control group and hyperthyroidism cured group(group C) (t=6.682,P<0.01).It was distinctly higher in hyperthyroidism group B than that in hyperthyroidism group A(t=2.385, P<0.05). And there was no distinct difference between the control group with hyperthyroidism group C in urine prMG, Alb and IgG (t=0.568, P>0.05).There was favorable correlation between the urine β2-MG, Alb and IgG with serum FT3 and FT4(the related coefficients were 0.98, 0.88, 0.93, 0.87, 0.94, and 0.85 respectively).Conclusion It is important to measure urine β2-MG together with Alb and IgG in early judgment of the location and degree of kidney injury, as well as the severity of disease in patients with hyperthyroidism.

参考文献/References:

[1] 张金池,陈林先,姚映斐,等.甲状腺疾病患者血清β2-MG含量与甲状腺激素的关系探讨.江西医学检验,2005,23(1):25-26.
[2] 湛贻璞.正确应用肾小球滤过功能检验十分重要.中华检验医学杂志,2007,30(4):374-376.
[3] 师凤国,寇祥,戴玉梅.甲亢患者血和尿β2MG与尿Alb检测的临床意义.标记免疫分析与临床,2005,12(1):54.
[4] 陈文斌.诊断学.北京:人民卫生出版社,2002:341-382.
[5] 淡以锐,黄兰玲,淡莉,等.5种尿微量蛋白的检测对糖尿病性肾病的早期诊断意义.吉林医学,1997,40(4):225-226.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[8]陈宁琳,鲍逸民,杨永青.血浆ATⅡ、NPY、IGF-1和hs-CRP水平测定在评估冠心病患者严重程度中的应用价值[J].国际放射医学核医学杂志,2014,38(3):167.[doi:10.3760/cma.j.issn.1673-4114.2014.03.007]
　Chen Ninglin,Bao Yimin,Yang Yongqing.The application value of plsama ATⅡ, NPY, IGF-1 and hs-CRP levels in evaluation of coronary heart disease severity[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):167.[doi:10.3760/cma.j.issn.1673-4114.2014.03.007]
[9]郑青,鲍逸民,杨永青.慢性心力衰竭患者血脂、血浆NT-ProBNP、CTnⅠ和hs-CRP水平测定的临床分析[J].国际放射医学核医学杂志,2014,38(4):232.[doi:10.3760/cma.j.issn.1673-4114.2014.04.006]
　Zheng Qing,Bao Yimin,Yang Yongqing.The clinical analysis of blood lipid and plasma NT-proBNP, CTnⅠ and hs-CRP levels determined in patients with chronic heart failure[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):232.[doi:10.3760/cma.j.issn.1673-4114.2014.04.006]
[10]赵若愚,鲍逸民,杨永青.血浆心肌细胞损伤标志物检测急性心肌梗死患者心肌损伤的临床研究[J].国际放射医学核医学杂志,2014,38(4):235.[doi:10.3760/cma.j.issn.1673-4114.2014.04.007]
　Zhao Ruoyu,Bao Yimin,Yang Yongqing.The clinical study of plasma myocardial cell damage markers in detecting myocardial injury patients with acute myocardial infraction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):235.[doi:10.3760/cma.j.issn.1673-4114.2014.04.007]
[11]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
　HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]

备注/Memo

备注/Memo:
收稿日期:2009-09-25。
通讯作者:崔丽群(E-mail:clql958@163.com)
更新日期/Last Update: 1900-01-01